
FOR IMMEDIATE RELEASE

China FDA Grants Pharmaceutical Manufacturing License to Nansha Manufacturing Facility

Hong Kong, June 30, 2016—Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Group", Stock Code: 950), an integrated research-driven and market-oriented pharmaceutical group in China is pleased to announce that Zhaoke Pharmaceutical (Guangzhou) Co., Ltd, a wholly own subsidiary company of the Group, has successfully obtained the first Pharmaceutical Manufacturing License for Tablet and Capsule from China Food and Drug Administration (CFDA).

Nansha Manufacturing Facility will be the key manufacturing and development facility of the Group. The total manufacturing area is over 43,000 M². This is one of the major milestones that we have accomplished. The facility includes about 6,000 M² on the 6th floor of manufacturing suites and 2,000 M² on the 2nd floor for quality and research development laboratories. The company has invested over 100 million RMB in the facility that is equipped with state-of-art machinery from Germany, Italy, and Japan.

"We are pleased that CFDA has granted the manufacturing license for Tablet and Capsule and we are excited to reach this important milestone for manufacturing pharmaceutical products," said Dr. Benjamin Li, Chief Executive Officer of the Group. "Not only can we manufacture solid dose form but also can we expedite our drug development program. The next milestone is to obtain Good Manufacturing Practice (GMP) certification and start commercial production in next year."

About Lee's Pharm

Lee's Pharm is a research-based biopharmaceutical company listed in Hong Kong with more than 20 years of operation in China's pharmaceutical industry. It is fully integrated with a strong infrastructure in drug development, manufacturing, sales and marketing. It has established extensive partnership with more than 20 international companies and currently has 15 products in the market place. Lee's Pharm focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. The company's development program is lauded with over 40 product candidates stemming from both internal R&D efforts and collaborations with US, European and Japanese companies, including promising compounds to treat liver cancer and pulmonary hypertension. The mission of Lee's Pharm is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information is available at <http://www.leespharm.com>.

Safe Harbour Statement

The performance and the results of operation of Lee's Pharm during the past years are historical in nature and past performance can be no guarantee of future results of the Lee's Pharm. This news release may contain forward-looking statements and opinions that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements and opinions. Neither Lee's Pharm nor the Directors, employees or agents of Lee's Pharm assume (a) any obligation to correct or update the forward-looking statements or opinions contained in this news release; and (b) any liability in the event that any of the forward-looking statements or opinions does not materialize or turns out to be incorrect.

For further information, please contact:

Vivian Fung

Tel: (852)2314-1282

Fax: (852)2314-1708

Email: info@leespharm.com